or Try an Advanced Search...

    Treatment Of Epilepsy Stocks List

    Symbol Grade Name % Change
    CPRX D Catalyst Pharmaceutical Partners, Inc. 3.83
    DRUG F Bright Minds Biosciences Inc. 2.71
    SUPN D Supernus Pharmaceuticals, Inc. -4.30
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Epilepsy Pharmaceutical Antidepressants Attention Deficit Hyperactivity Disorder Central Nervous System Disease Chemical Compounds Chloride Clinical Research Clinical Trial Clinical Trial Product Depression Disorders Drug Discovery Drugs Health Sciences Hyperactivity Disorder Investigational New Drug Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Medication

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Epilepsy stocks.

    Symbol Grade Name Weight
    IBRN D iShares Neuroscience and Healthcare ETF 6.19
    PJP A PowerShares Dynamic Pharmaceuticals 3.92
    FBT D First Trust Amex Biotech Index Fund 3.34
    PBE C PowerShares Dynamic Biotech & Genome 2.99
    PSCH C PowerShares S&P SmallCap Health Care Portfolio 2.92
    View all Treatment Of Epilepsy ETFs...
    Compare ETFs
    Compare IBRN to PBE Compare PBE to PSCH Compare PJP to PBE

        Treatment Of Epilepsy Stocks Recent News

        Date Stock Title
        May 10 SUPN Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
        May 9 CPRX HHS panel to vote in Nov. on DMD screening for newborns
        May 9 SUPN Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
        May 9 SUPN Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
        May 9 CPRX Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
        May 9 SUPN Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
        May 9 SUPN Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
        May 8 SUPN Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
        May 8 SUPN Supernus Pharmaceuticals reports mixed Q1 results; reaffirms FY24 outlook
        May 8 CPRX Catalyst Pharmaceuticals Non-GAAP EPS of $0.38 beats by $0.08, revenue of $98.44M misses by $0.33M
        May 8 CPRX Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
        May 8 SUPN Supernus Announces First Quarter 2024 Financial Results
        May 7 SUPN Supernus Pharmaceuticals Q1 2024 Earnings Preview
        May 7 CPRX Catalyst Pharmaceuticals Q1 2024 Earnings Preview
        May 7 SUPN M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
        May 7 SUPN Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Epilepsy Pharmaceutical Antidepressants Attention Deficit Hyperactivity Disorder Central Nervous System Disease Chemical Compounds Chloride Clinical Research Clinical Trial Clinical Trial Product Depression Disorders Drug Discovery Drugs Health Sciences Hyperactivity Disorder Investigational New Drug Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Medication
        Treatment Of Epilepsy

        Treatment of epilepsy typically involves medications, lifestyle changes, and sometimes surgery. Medications are the most common form of treatment and are used to control seizures. Lifestyle changes may include avoiding triggers, such as sleep deprivation, stress, and certain foods, and getting regular exercise. Surgery may be recommended in some cases to remove the part of the brain that is causing the seizures.

        Browse All Tags